Patricia Lowe
05Dec2016

Patricia Lowe, LPN, CCRC

23103 Dover Drive, Land O'Lakes, FL 34639 813-625-4029 patricialowe5633@gmail.com

BUSINESS ADDRESS:
USF Health Byrd Alzheimer's Institute
4001 East Fletcher Avenue | Tampa, FL 33613
Office (813) 396-0606| Fax (813) 905-8890
Visit us online: http://alz.health.usf.edu
Email: plowe@health.usf.edu

Experience

Clinical Research Associate/Study Coordinator
USF Health Byrd Alzheimer's Institute
December 5, 2016- Present
- Coordinate Clinical Trials for the Mobile Unit
- Patient Care
- Blood draws and IV therapy

Research Nurse
Office of Clinical Research University of South Florida
August 12, 2014- December 2, 2016
- Coordinate Clinical Trials
- Patient Care
- Blood draws and IV therapy

LPN- Clinical Research Coordinator University of South Florida
December 2010 – August 11, 2014
Department of Neurology, College of Medicine
- Parkinson's and Movement Disorders clinical trials
- Nurse Research Coordinator
- Patient care
- Blood draws and IV therapy

Licensed Practical Nurse University of South Florida Physicians Group
June 2001 – December 2010
Dermatology Phototherapy Technician
Neurology Specialty Clinic – Multi-Specialty Clinic
- Patient care for movement disorders, pain management, MS and general neurology diagnosis
- IV therapy and blood draws for clinical trial patients
- Telephone triage, lab procedures,
- Hospital admissions and referrals

Patricia Lowe, LPN, CCRC

23103 Dover Drive, Land O'Lakes, FL 34639 813-625-4029 patricialowe5633@gmail.com

Licensed Practical Nurse
August 2009 – July 1, 2014 LifePath Hospice, Tampa, FL
(Weekend position as needed)

- Paliative care for hospice patients
- Family and patient counseling

Licensed Practical Nurse
August 2000 – June 2001 Cigna Health Care, Tampa, FL
Internal Medicine/Family Practice

- General patient care responsibilities
- Patient referrals and immunizations
- Telephone triage

Administrative and Licensed Practical Nurse
August 1987 – August 2000 Institute for the Disorders of Aging, Tallahassee, FL

- General Patient care including, Balance Master, Equitest, Humphry Visual Fields and Mini-Mental Status Examinations
- Patient referrals
- Telephone triage

Licensed Practical Nurse
July 1994 – August 1995 Ricardo Ayala, M.D. Tallahassee, FL

- Clinical trial nurse for TPA stoke study
- Coordinated with hospitals regarding stroke study candidates
- Administration and coordination of all clinical trial medications

Education

Tallahassee Communicate College, Tallahassee, FL
1990-1994

- Registered Nurse Prerequisite Course

Lively Vocational Technical School, Tallahassee, FL
1991-1993

- Licensed Practical Nurse

Tampa Medical College, Tampa, FL
1983-1984

- Certified Medical Assistant

Interests

Neurological Disorders including pain management, movement disorders and clinical trials and research.

References

References are available on request.

RESEARCH STUDIES

1. *"A Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/day) as Treatment in Patients with Huntington's Disease", S*ite Investigator: Juan Sanchez-Ramoz, Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.
2. *"Phase 3 Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Determine the Efficacy of Topical SGX301 (Synthetic Hypericin) and Fluorescent Bulb-Light Irradiation for the Treatment of Cutaneous T-Cell Lymphoma",* Site Investigator: Nishit Patel, Sponsor: Soligenix Inc.
3. *"A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Dosing Regimens in Patients with Moderate-to-Severe Plaque Psoriasis"*, Site Investigator: Nishit Patel, Sponsor: Eli Lilly and Company.
4. R668-AD-1225 - *An Open-Label Study of Dupilumab In Patients with Atopic Dermatitis Who Participated in Previous Dupilumab Clinical Trials"*, Site Investigator: Christopher G. Nelson, MD; Sponsor: Regeneron Pharmaceuticals, Inc.
5. *R668-AD-1415 – "A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of Multiple Dupolumab Dose Regimens Administered as Monotherapy for Maintaining Treatment Response in Patients with Atopic Dermatitis*", Site Investigator: Christopher G. Nelson, MD; Sponsor: Regeneron Pharmaceuticals, Inc.
6. *R668-AD-1334 - "A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients with Moderate-to-Severe Atopic Dermatitis*", Site Investigator: Christopher G. Nelson, MD; Sponsor: Regeneron Pharmaceuticals, Inc.
7. *R668-AD-1224 – "A Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Long-Term Safety of Dupilumab in Adult Patients with Moderate-to-Severe Atopic Dermatitis"*, Site Investigator: Christopher G. Nelson, MD; Sponsor: Regeneron Pharmaceuticals, Inc.
8. *A Phase 4, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Study of the Efficacy and Safety of Apremilast (CC-10004), in Subjects with Moderate Plaque Psoriasis,* Site Investigator: Nishit Patel, Sponsor: Celgene Corporation.
9. *M13-674: A Phase 3 Multicenter Double-Blind Randomized Parallel-Arm, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Adalimumab for Treatment of Nail Psoriasis in Subjects with Chronic Plaque Psoriasis,* Site Investigator: Nishit Patel, Sponsor: AbbVie Inc.
10. *A multicenter open label uncontrolled study of the long term safety and efficacy of calcitriol 3mcg/g ointment applied twice daily for 26 weeks in pediatric subjects (2 to 17 years of age) with mild to moderate plaque psoriasis*; Site Investigator: Christopher G. Nelson; Sponsor: Galderma R&D, LLC
11. *Effect of Calcipotriol plus Betamethasone Dipropionate Gel on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to 16 Years, 11 months) with Scalp and Body Psoriasis;* Site Investigator: Christopher G. Nelson, MD; Sponsor: Leo Pharma A/S
12. *An Open-label, Multi-center, 52-Week, Long-term Study to Evaluate the Safety and Efficacy of 50 µg/g M518101 in Subjects with Plaque Psoriasis*; Site Investigator: Christopher G. Nelson; Sponsor: Maruho North America Inc.
13. *Safety and efficacy of escalating doses of two LEO 43204 formulations applied once daily for two consecutive days on full face or approximately 250 cm^2 (40 in^2) on the chest in subjects with actinic keratosis;* Site Investigator: Christopher G. Nelson, MD; Sponsor: Leo Pharma A/S
14. *A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis*; Site Investigator: Christopher G. Nelson; Sponsor: Eli Lilly and Company
15. *A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients with Moderate-to-Severe Plaque Psoriasis;* Site Investigator: Christopher G. Nelson; Sponsor: Eli Lilly and Company

A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2; Site Investigator: Christopher G. Nelson; Sponsor: Amgen

List of Parkinson's Disease Research Studies

1. Phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety, tolerability and efficacy of ADX48621 in the treatment of levodopa induced dyskinesia in patients with Parkinson's disease

2. A Phase 3, 12-Week, Double-Blind, Placebo- and Active-Controlled Efficacy and Safety Study of Preladenant in Subjects with Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P04938)

3. A MULTI-CENTER, OPEN-LABEL STUDY TO ASSESS THE LONG-TERM SAFETY OF DROXIDOPA IN SUBJECTS WITH PRIMARY AUTONOMIC FAILURE, DOPAMINE BETA HYDROXYLASE DEFICIENCY OR NONDIABETIC NEUROPATHY AND SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION

4. An Open-Label, 12-Month Safety and Efficacy Study of Levodopa – Carbidopa Intestinal Gel in Levodopa-Responsive Subjects with Advanced Parkinson's Disease and Severe Motor-Fluctuations Despite Optimized Treatment with Available Parkinson's Disease Medications

5. A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of Pimavanserin in the Treatment of Psychosis in Parkinson's Disease

6. A PHASE IIIb, MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF DYSPORT USING 2 mL DILUTION IN ADULTS WITH CERVICAL DYSTONIA

7. A Phase 3, Double-Blind, Placebo- and Active-Controlled Dose-Range-Finding Efficacy and Safety Study of Preladenant in Subjects With Early Parkinson's Disease (Phase 3 Protocol No. P05664)

8. A Phase 1, open label, single ascending dose study to investigate the safety, tolerability and pharmacokinetics of PYM50028 in non-patient volunteers (P58/09ME/00/01-FR)

9. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of CVT-301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena)

10. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy, Safety and Tolerability of APL-130277 in Levodopa Responsive Patients with Parkinson's Disease complicated by Motor Fluctuations ("OFF" Episodes)

11. A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3, Protocol No. P06153)

12. An open-label treatment study to evaluate the safety, tolerability and efficacy of AFQ056 in Parkinson's patients with L-dopa induced dyskinesias